NCT02236741View on ClinicalTrials.gov

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

CompletedOBSERVATIONAL
Enrollment

26,814

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

December 31, 2010

Conditions
Heart Failure
Interventions
DRUG

Mirapexin® (Sifrol®)

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02236741 - The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia | Biotech Hunter | Biotech Hunter